Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardinal Health, Inc. (NYSE: CAH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cardinal Health is an Ohio corporation whose common shares trade on the New York Stock Exchange under the symbol CAH, as noted in multiple Form 8-K filings. These documents give investors detailed insight into the company’s financial condition, governance, capital structure, and material events.
Cardinal Health regularly files Form 8-K current reports to announce significant developments. Recent 8-K filings include disclosures about quarterly and annual financial results, updates to fiscal 2026 non-GAAP earnings per share outlook, entry into material definitive agreements such as credit facilities and receivables purchase amendments, public offerings of notes to help fund acquisitions like Solaris Health, and the completion of those offerings. Other 8-Ks document matters such as the 2025 Annual Meeting of Shareholders and voting results on director elections, say-on-pay, and auditor ratification.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) offers extensive information on corporate governance, Board composition, executive compensation, and shareholder voting items. Cardinal Health’s proxy materials describe its strategic priorities, fiscal performance highlights, Board skills and refreshment, and engagement with shareholders.
Through Stock Titan, users can review Cardinal Health’s periodic and current reports and use AI-powered tools to summarize key points from lengthy filings. These tools help explain complex sections, highlight items such as non-GAAP metrics definitions, capital markets transactions, and credit agreements, and make it easier to track themes like Specialty growth, distribution network investments, and capital allocation. The filings page also surfaces relevant exhibits, including indentures, underwriting agreements, and amendments to financing arrangements, giving a structured view of Cardinal Health’s obligations and governance framework.
Cardinal Health, Inc. reported that several of its receivables financing subsidiaries and major banking partners entered into a First Amendment to an existing Fifth Amended and Restated Receivables Purchase Agreement originally dated September 1, 2023. The principal change is an extension of the term of this receivables financing facility to September 28, 2028, helping maintain access to funding backed by customer receivables.
Key counterparties include Wells Fargo, Liberty Street Funding, The Bank of Nova Scotia, PNC Bank, Bank of America, Victory Receivables Corporation and MUFG Bank. These institutions or their affiliates also provide other services to Cardinal Health, such as acting as dealers under its commercial paper program and participating in its $2.0 billion revolving credit facility.
Cardinal Health's proxy highlights strong fiscal 2025 operating and governance outcomes. GAAP diluted EPS was $6.45 (prior year included a $617 million after-tax goodwill impairment of $2.50 per share). Non-GAAP diluted EPS was $8.24, a 9% increase year-over-year. The company generated $2.4 billion in operating cash flow, returned over $1.2 billion to shareholders ($750 million in repurchases and $494 million in dividends), invested $547 million in the business, and deployed $5.3 billion on acquisitions including ION, GI Alliance and Advanced Diabetes Supply Group. Performance share units for the 2023–2025 cycle settled at 212% of target after a 20% TSR modifier; three‑year TSR was 235.5% vs. 9.4% for the S&P 500 Health Care Index. Governance disclosures detail an independent, non-executive chairman, recent director additions (Messrs. Musslewhite and Ramakrishna), board refreshment practices, and executive compensation governance, including a disclosed CEO-to-median pay ratio of 261:1.
Cardinal Health's proxy highlights strong fiscal 2025 operating and governance outcomes. GAAP diluted EPS was $6.45 (prior year included a $617 million after-tax goodwill impairment of $2.50 per share). Non-GAAP diluted EPS was $8.24, a 9% increase year-over-year. The company generated $2.4 billion in operating cash flow, returned over $1.2 billion to shareholders ($750 million in repurchases and $494 million in dividends), invested $547 million in the business, and deployed $5.3 billion on acquisitions including ION, GI Alliance and Advanced Diabetes Supply Group. Performance share units for the 2023–2025 cycle settled at 212% of target after a 20% TSR modifier; three‑year TSR was 235.5% vs. 9.4% for the S&P 500 Health Care Index. Governance disclosures detail an independent, non-executive chairman, recent director additions (Messrs. Musslewhite and Ramakrishna), board refreshment practices, and executive compensation governance, including a disclosed CEO-to-median pay ratio of 261:1.
Cardinal Health, Inc. filed an 8-K reporting execution of a Third Supplemental Indenture dated August 27, 2025, with The Bank of New York Mellon Trust Company, N.A., as trustee, and included forms of two note series: 4.500% Notes due 2030 and 5.150% Notes due 2035. The filing incorporates the original Indenture dated June 2, 2008, and includes legal opinions and consents from Cardinal Health's General Counsel and White & Case LLP, plus an embedded Inline XBRL cover page.
The disclosure documents appear to support issuance or amendment of long-term debt instruments by the company and provide legal and trustee documentation required for such securities. The filing is signed by Aaron E. Alt, Chief Financial Officer.
Cardinal Health (CAH) Form 144 notice reports a proposed sale of 21,367 common shares through Merrill Lynch on 08/20/2025 with an aggregate market value of $3,216,330.00. The filing shows the shares were acquired on 08/15/2025 from Cardinal Health, Inc. as 13,088 shares from performance stock vesting and 8,279 shares from restricted stock vesting. No securities were reported sold by the same person in the past three months. The document includes the required representation that the seller is not aware of undisclosed material adverse information and references potential Rule 10b5-1 plan considerations.
Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00). After the reported dispositions she beneficially owned 53,428 shares. The filing notes the weighted-average price and offers to provide detailed per-trade quantities and prices on request. No derivative transactions or additional acquisitions are reported in this Form 4.
Insider transactions reported for Cardinal Health, Inc. (CAH). The Form 4 shows Jason M. Hollar, listed as Chief Executive Officer and an officer reporting person, sold common shares on 08/20/2025 in two separate sets of transactions. The first sale disposed of 12,944 shares at a weighted average price of $149.40, leaving 222,957 shares beneficially owned. The second sale disposed of 22,957 shares at a weighted average price of $150.40, leaving 200,000 shares beneficially owned following that reported transaction.
The filings note the prices are weighted averages from multiple trades within specified ranges and state the reporting person will provide further breakdowns on request. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Mary C. Scherer, Chief Accounting Officer of Cardinal Health, Inc. (CAH), reported multiple transactions on Form 4. She was granted 1,203 restricted stock units (RSUs) on 08/15/2025 that vest in three equal annual installments beginning 08/15/2026. To satisfy tax withholding on vested awards, 2,572 shares were withheld (reported as a disposition at $150.22, reflecting prior close). Separately, 6,766 common shares were sold on 08/19/2025 at a weighted average price of $149.25, with sale prices ranging $148.94–$149.60. After these transactions her reported beneficial ownership of common shares is 3,556 shares.
Cardinal Health insider filings show multiple equity transactions by Michelle D. Greene, the company's Chief Information Officer. On 08/15/2025 Greene received a grant of 3,476 restricted share units (RSUs) that vest in three equal annual installments beginning 08/15/2026. The filing also discloses withholding of 9,968 shares to satisfy taxes related to the vesting of 6,787 RSUs and 16,362 performance share units, using a prior-business-day closing price of $150.22. On 08/19/2025 Greene sold a total of 13,500 common shares in multiple transactions at weighted-average prices of $148.76 and $149.28, reducing beneficial ownership from 38,444 to 14,976 shares.
Mason Stephen M, an officer (CEO, GMPD Segment) of Cardinal Health, Inc. (CAH), reported multiple transactions in the companys common stock on 08/15/2025 and 08/19/2025. On 08/15/2025 he received a grant of 8,957 restricted stock units (RSUs) that vest in three equal annual installments beginning 08/15/2026, increasing his beneficial holdings to 98,471 shares. Also on 08/15/2025, 30,811 shares were withheld to satisfy tax obligations related to vesting, reducing holdings to 67,660 shares. On 08/19/2025 he sold a total of 41,575 shares in multiple transactions at weighted average prices of about $147.87, $148.83, and $149.39, resulting in 26,085 shares beneficially owned after the reported sales. The Form 4 discloses price ranges and notes weighted-average pricing for those sales.
Deborah Weitzman, an officer (CEO, PSS Segment) of Cardinal Health, reported two transactions on 08/15/2025. She was granted 10,694 restricted share units (RSUs) that vest in three equal annual installments beginning 08/15/2026, increasing her beneficial ownership to 98,923 common shares. Separately, 24,128 shares were withheld to satisfy tax obligations related to the vesting of 14,966 RSUs and 39,100 performance share units, executed at a prior-business-day closing price of $150.22, leaving beneficial ownership of 74,795 common shares. The form is signed by an attorney-in-fact on 08/19/2025.